Innovative Therapeutics Northern Biologics specializes in developing novel therapeutic antibodies focused on targeting key signaling pathways in cancer and fibrosis, presenting opportunities to collaborate on advanced biologics development and phenotype-specific antibody solutions.

Strong Industry Backing As a wholly owned subsidiary of Boehringer Ingelheim since April 2020, Northern Biologics benefits from extensive industry resources and an expanding oncology portfolio, making it a strategic partner for sophisticated biotech and pharmaceutical companies.

Research Excellence Leveraging cutting-edge phage display platforms developed at the University of Toronto, Northern Biologics offers access to innovative antibody generation capabilities that can complement or enhance partner R&D efforts.

Growing Market Presence With recent acquisitions and a solid revenue base estimated between one to ten million dollars, the company presents growth potential in the biotech space, targeting tumor microenvironment therapies, ideal for partners looking to expand in oncology markets.

Technological Edge Utilizing advanced biotech research infrastructure and digital tools such as MySQL, WordPress, and analytics platforms, Northern Biologics maintains a modern technological backbone that supports scalable research and development collaborations.